Role of O-GlcNAc-ylation on tumor progression
Role of O-GlcNAc-ylation on tumor progression
批准号:
10444126
负责人:
Lalita A. Shevde
金额:
$33.97万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-03-10 至 2027-02-28
关键词:
ABCB1 geneAntineoplastic AgentsAttenuatedBiological ModelsBiological ProcessBreast Cancer CellBreast Cancer ModelCarbohydratesCell Cycle ProgressionCell ProliferationCellsCharacteristicsChemicalsChemoresistanceDNA RepairDNA Repair GeneDiabetes MellitusDietEmbryonic DevelopmentErinaceidaeEventGLI Family ProteinGLI geneGeneticGenetic TranscriptionGlucoseHomeostasisHumanHydroxyl RadicalHyperglycemiaImmuneImpairmentInvestigationLicensingLinkMalignant NeoplasmsMammary NeoplasmsMass Spectrum AnalysisMetabolicMetabolismMicroclimateModelingModificationMolecularNeurodegenerative DisordersNormal tissue morphologyNutritional statusOutcomePathway interactionsPhenotypeProcessProliferatingProteinsProteomicsReportingResearch DesignRoleSerineSideSignal PathwaySignal TransductionSiteStructureTestingThreonineTissuesTumor Cell InvasionUp-Regulationbasecancer cellcancer typechemotherapeutic agentcytotoxicglucose uptakemalignant breast neoplasmmouse modelneoplastic cellnovelpatient derived xenograft modelprogramsresponsesmall molecule inhibitorsmoothened signaling pathwaysuccesssugartooltranscription factortriple-negative invasive breast carcinomatumortumor progression
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract
O-linked ß-N-acetylglucosamine (O-GlcNAc) is a sugar attachment to the side chain hydroxyl of a serine or
threonine residue on proteins. O-GlcNAcylation controls key signaling and biological processes such as signal
transduction, transcription, cell cycle progression, and metabolism. Perturbations in O-GlcNAc homeostasis
have been linked with diabetes, cancer, and neurodegenerative diseases. Increased glucose levels channel flux
through the Hexoseamine Biosynthetic Pathway (HBP), culminating in increased O-GlcNAc levels.
The activity of HBP and consequently cellular O-GlcNAc-ylation are elevated in several cancer types, including
breast cancer. We recently reported that inhibiting HBP activity significantly decreased the invasive phenotype
of breast tumor cells. We surmised that abundance of glucose, a readily-metabolizable carbohydrate, will drive
flux through HBP, resulting in enrichment of a portfolio of proteins that are modified by O-GlcNAc-ylation. Using
unbiased proteomics analysis, we identified that elevated glucose culture conditions enrich for O-GlcNAc-
modified GLI proteins, transcription factors of the Hedgehog (Hh) pathway. Importantly, we identified that in
elevated glucose conditions, O-GlcNAc-modification of GLI exacerbates Hh/GLI activity; and inhibiting HBP
mitigated this effect. We hypothesize that HBP-directed O-GlcNAc-ylation fundamentally programs invasive and
chemoresistant attributes in tumor cells through activating Hh/GLI signaling.
In Aim 1 we will determine the molecular underpinnings of HBP-directed O-GlcNAc-ylation of GLI. We will
determine the causes and consequences of GLI O-GlcNAc-ylation. We will first identify engagement of the HBP
in O-GlcNAc-modification of GLI proteins. Next, we will undertake investigations to identify establish the
mechanistic basis of how HBP signaling engages O-GlcNAc-modified GLI to program invasive and
chemoresistant attributes in tumor cells.
In Aim 2 we will evaluate the impact of an elevated O-GlcNAc landscape on molecular and cellular attributes of
the mammary tumor and the associated immune microclimate using two distinct and complementary syngeneic
mouse models of mammary cancer. To enrich the relevance, we will also evaluate human TNBC and PDX model
systems. We will test if inhibiting GLI activity, in the context of elevated O-GlcNAc, uncouples the influence of O-
GlcNAc-ylation on invasive and chemoresistant attributes of mammary tumor cells.
Relevance: Our proposed studies are structured to systematically investigate how O-GlcNAc-driven metabolic
reprogramming in cancer cells connects at the molecular level to aberrantly activate Hh/GLI signaling. The
cumulative outcomes will create mechanistic understanding of how O-GlcNAc-ylation programs tumor invasion,
progression and response to anti-neoplastics.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of O-GlcNAc-ylation on tumor progression
-
批准号:10589810
-
项目类别:
-
资助金额:$33.29万
-
财政年份:2022
-
负责人:Lalita A. Shevde
-
依托单位:
Roadmap for America's Cancer Explorers for the 21st Century (Race 21)
-
批准号:10252847
-
项目类别:
-
资助金额:$41.79万
-
财政年份:2020
-
负责人:Lalita A. Shevde
-
依托单位:
Roadmap for America's Cancer Explorers for the 21st Century (Race 21)
-
批准号:10478045
-
项目类别:
-
资助金额:$41.79万
-
财政年份:2020
-
负责人:Lalita A. Shevde
-
依托单位:
Roadmap for America's Cancer Explorers for the 21st Century (Race 21)
-
批准号:10023708
-
项目类别:
-
资助金额:$41.79万
-
财政年份:2020
-
负责人:Lalita A. Shevde
-
依托单位:
Mechanisms of resistance to cancer therapeutics
-
批准号:8694974
-
项目类别:
-
资助金额:$30.5万
-
财政年份:2014
-
负责人:Lalita A. Shevde
-
依托单位:
Mechanisms of resistance to cancer therapeutics
-
批准号:8830937
-
项目类别:
-
资助金额:$30.5万
-
财政年份:2014
-
负责人:Lalita A. Shevde
-
依托单位:
Mechanisms of resistance to cancer therapeutics
-
批准号:9079414
-
项目类别:
-
资助金额:$30.5万
-
财政年份:2014
-
负责人:Lalita A. Shevde
-
依托单位:
Molecular determinants of breast cancer malignancy
-
批准号:8458999
-
项目类别:
-
资助金额:$40.72万
-
财政年份:2011
-
负责人:Lalita A. Shevde
-
依托单位:
Molecular determinants of breast cancer malignancy
-
批准号:8653835
-
项目类别:
-
资助金额:$29.59万
-
财政年份:2011
-
负责人:Lalita A. Shevde
-
依托单位:
Molecular determinants of breast cancer malignancy
-
批准号:8261842
-
项目类别:
-
资助金额:$30.81万
-
财政年份:2011
-
负责人:Lalita A. Shevde
-
依托单位:
Molecular determinants of breast cancer malignancy
-
批准号:8106603
-
项目类别:
-
资助金额:$30.81万
-
财政年份:2011
-
负责人:Lalita A. Shevde
-
依托单位:
Cancer Research Training and Education Coordination
-
批准号:10411026
-
项目类别:
-
资助金额:$15.59万
-
财政年份:1997
-
负责人:Lalita A. Shevde
-
依托单位:
Cancer Research Training and Education Coordination
-
批准号:10629225
-
项目类别:
-
资助金额:$15.59万
-
财政年份:1997
-
负责人:Lalita A. Shevde
-
依托单位:
海外基金